by The global HIV diagnostics market was estimated at USD 0.99 billion in 2022 and it is expected to surpass around USD 1.7 billion by 2032, poised to grow at a CAGR of 5.53% from 2023 to 2032. The HIV diagnostics market in the United States was accounted for USD 248.9 million in 2022.
Key Pointers
- Asia Pacific led the market with the largest revenue share of 36% in 2022.
- Latin America is anticipated to grow at the fastest CAGR of 6.93% from 2023 to 2032.
- By Product, the consumables segment held the largest revenue share of 48% in 2022.
- By Product, the software & services segment is expected to expand at the fastest CAGR of 6.93% over the forecast period.
- By Mode, the lab-based testing segment contributed more than 90% of revenue share in 2022.
- By Mode, the self-testing segment is predicted to grow at the fastest CAGR of 10.63% over the forecast period.
- By Test Type, the antibody test type segment led the market with largest revenue share of 54% in 2022.
- By End-use, the diagnostic laboratories segment generated the maximum market share of 37% in 2022.
The HIV diagnostics market is a critical component of the broader healthcare landscape, dedicated to the detection and monitoring of Human Immunodeficiency Virus (HIV) infections. This overview provides a comprehensive look at the key elements that define the market, including its scope, major players, testing methods, and the driving factors influencing its dynamics.
Market Growth
The growth of the HIV diagnostics market is propelled by several key factors. Firstly, the persistent global prevalence of HIV/AIDS underscores the ongoing demand for robust diagnostic solutions. Advances in technology, particularly the integration of molecular diagnostics and Point-of-Care testing, contribute significantly to heightened accuracy and accessibility, further expanding the market. Government initiatives and increased awareness campaigns advocating for widespread testing have played a pivotal role in driving market growth, fostering a proactive approach to HIV detection and management. Additionally, the evolving trend towards decentralized testing models aligns with the imperative to reach underserved populations, promoting inclusivity and comprehensive healthcare. These growth factors collectively underscore the dynamic nature of the HIV diagnostics market, positioning it as a vital player in global public health efforts.
Get a Sample: https://www.visionresearchreports.com/report/sample/40942
Report Scope of the HIV Diagnostics Market
| Report Coverage | Details |
| Market Revenue by 2032 | USD 1.7 billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.53% |
| Revenue Share of Asia Pacific in 2022 | 36% |
| CAGR of Latin America from 2023 to 2032 | 6.93% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Read More: https://www.heathcareinsights.com/womens-health-diagnostics-market/
Market Dynamics
Drivers
Global Prevalence and Persistence:
The continued prevalence of HIV/AIDS worldwide serves as a primary driver for the sustained demand for effective diagnostics.
Decentralized Testing Models:
The shift towards decentralized testing models enhances accessibility, particularly in remote or resource-constrained regions, fostering market growth.
Restraints
Stigma and Societal Barriers:
The persistent social stigma surrounding HIV/AIDS creates barriers to testing, hindering individuals from seeking diagnostic services due to fear of discrimination or social exclusion.
Limited Access in Resource-Constrained Settings:
Inadequate healthcare infrastructure and limited access to diagnostic facilities in certain resource-constrained regions pose a significant restraint, impeding the widespread availability of HIV diagnostics.
Opportunities
Innovative Point-of-Care Technologies:
The development and adoption of innovative Point-of-Care (POC) diagnostic technologies present a significant opportunity to enhance accessibility, particularly in remote or underserved regions, by providing rapid and decentralized testing options.
Integration of Artificial Intelligence (AI):
The integration of Artificial Intelligence (AI) in diagnostic processes can enhance the accuracy of HIV testing, streamline data analysis, and contribute to the development of more efficient and reliable diagnostic tools.
Product Insights
The market is segmented into consumables, instruments, and software & services. The consumables segment accounted for the largest revenue share of 48% in 2022 owing to the prevalence of HIV cases and the need to improve the accuracy of the results. Various screening and confirmatory tests are conducted for the diagnosis of HIV-1, HIV-2, and group O incidences. These tests have primary applications to screen and differentiate between the various groups and subtypes of human immunodeficiency virus. Therefore, accurate consumables need to be used to improve the quality of results and treatments.
Moreover, the software & services segment is expected to grow at the fastest CAGR of 6.93% over the forecast period due to technological advancements and increasing awareness regarding HIV and AIDS. Various government campaigns to create awareness and reduce the stigma around these diseases can also be attributed to this growth. For instance, Let’s Stop HIV Together (Together) is a campaign by the Centers for Disease Control and Prevention, which aims to raise awareness regarding HIV, promote diagnostics & testing, and reduce stigma around it.
Mode Insights
On the basis of mode, the market is further segmented into self-testing and lab-based testing. The lab-based testing segment contributed the largest market share of 90% in 2022 owing to the accuracy of their results. Lab-based tests are performed in diagnostic laboratories or healthcare facilities by skilled professionals using advanced equipment. It gives accurate results, allows for prolonged monitoring, and is essential for confirmatory testing and complex analysis. Rapid and point-of-care testing technologies also allow for early intervention and reduce the time between testing and the start of the treatment. The market has enormous potential to increase accessibility, accuracy, and efficiency, ultimately leading to better outcomes for HIV patients and global disease-fighting efforts.
The self-testing segment is anticipated to grow at the fastest CAGR of 10.63% over the forecast period due to their user-friendliness and convenience. Self-testing allows individuals to run diagnostic tests at home using a self-collection kit and interpret the results independently. It offers ease, and anonymity, and facilitates early detection. Self-test kits have become more accessible with higher accuracy and faster turnaround times. It has given people the ability to take control of their health and overcome challenges, such as stigma and inconvenience with traditional testing techniques. Both self-testing and lab-based testing approaches aid in HIV diagnosis by catering to different needs and preferences, promoting awareness, and enabling effective viral control.
Test Type Insights
On the basis of test types, the global market has been further categorized into antibody tests, viral load tests, CD4 tests, and others. The antibody test type segment dominated the industry with largest revenue share of 54% in 2022. The segment is projected to remain dominant growing at the fastest CAGR of 5.95% during the forecast period. The growth of this segment can be attributed to the presence of several antibody tests.
These tests include HIV-1 screening, confirmatory HIV-2, and Group-O tests, which can be further divided into 3rd- and 4th-generation ELISA tests, POC and non-POC dried blood spot tests, western blot, and line immunoassays. These tests are increasingly being used in disease subtyping, screening, and confirmation. The confirmatory western blot test is regarded as 100% accurate post-antibody screening. The high utilization rates and accuracy of these tests are further expected to drive the antibody testing segment growth.
End-use Insights
On the basis of end-use, the market has been further segmented into diagnostic laboratories, hospitals & clinics, home settings, and others. The diagnostic laboratories segment held the largest revenue share of 37% in 2022 as diagnostic laboratories conduct rigorous testing and analysis using advanced technology and qualified personnel, resulting in accurate results. The home settings segment is expected to register the fastest CAGR of 8.3% over the forecast period.
The market is reliant on collaboration among all segments, including diagnostic laboratories, hospitals & clinics, and home settings to work together to ensure that people have access to accurate testing, counseling, and appropriate care to assist in the improvement of public health worldwide. The growth of this segment can be attributed to the privacy and convenience offered by home-based HIV testing kits, which allow individuals to administer tests and receive results in the privacy of their own homes.
Regional Insights
Asia Pacific dominated the market with the largest revenue share of 36% in 2022 owing to technological advancement, an increase in the number of people suffering from HIV and AIDS, and increasing awareness regarding the same in this region. According to an article published by The Indian Express in August 2022, approximately 24.01 lakh people in India are diagnosed with HIV. The increasing health expenditure and efforts by governments in these regions to increase awareness and promote treatment are likely to boost market growth in the years to come.
Latin America is expected to grow at the fastest CAGR of 6.93% during the forecast period owing to the increasing awareness about diagnostic testing in the region. According to the article published by the Pan American Health Organization, in November 2020, HIV infection cases in Latin America have increased by 20% in the last decade. The region has witnessed a significant increase in healthcare expenditure, leading to greater investment in research and development activities.
Key Companies
- Alere Inc.
- Abbott
- Bristol-Myers Squibb Company
- Janssen Global Services, LLC
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- VIIV Healthcare
- BD
- Beckman Coulter, Inc.
- Sysmex Europe SE
- Apogee Flow Systems
- Point Care
- Zyomtronix, Inc.
- Mylan N.V.
- F. Hoffmann-La Roche Ltd.
- Siemens Healthcare GmbH
- QIAGEN
HIV Diagnostics Market Report Segmentations:
By Product
- Consumables
- Instruments
- Software and Services
By Mode
- Self-test
- Lab-based
By Test Type
- Antibody Test
- HIV-1 Screening Tests
- ELISA/EIA
- Home Access Dried Blood Spot
- Rapid Tests (Dot plot, Agglutination Tests)
- HIV-1 Antibody Confirmatory Tests
- Western Blot Test
- Indirect Immunofluorescent Antibody Assay (IFA)
- Line Immunoassay
- RadioImmunoPrecipitation Assay (RIPA)
- HIV-2 & Group O Diagnostic Tests
- Blood Antibody Tests
- Dried Blood Spot (DBS) Test
- Others and (Oral, Urine)
- HIV-1 Screening Tests
- Viral Load Test
- CD4 Test
- Others
By End-use
- Diagnostic Laboratories
- Hospitals & Clinics
- Home Settings
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/40942
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
